Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review

October 2021 | 36 pages | ID: L69029FEF62EN
GlobalData

Abstracts

Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Living Cell Technologies Ltd (LCT) is a biotechnology company that discovery, development and commercialization of novel therapeutics for the treatment of debilitating conditions such as Parkinson’s disease, obesity and migraine. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT develops its candidates based on its proprietary encapsulation technology, Immupel. Its pipeline products include, NTCELL an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It is in Phase IIb clinical trials for the treatment of Parkinson's disease. LP-003, a peptide drug that reduces caloric intake. It is in preclinical phase for treatment of obesity; LC-002 is a novel calcitonin gene-related peptide antagonist in preclinical phase for treatment of migraine. The company has partnerships collaborations with universities and pharmaceutical companies for development of its product candidates. LCT is headquartered in Auckland, New Zealand.

Living Cell Technologies Ltd Key Recent Developments

Jul 16,2021: LCT appoints interim CEO
Jan 25,2021: LCT CEO Dr Ken Taylor signals intention to retire

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Living Cell Technologies Ltd - Key Facts
Living Cell Technologies Ltd - Key Employees
Living Cell Technologies Ltd - Key Employee Biographies
Living Cell Technologies Ltd - Major Products and Services
Living Cell Technologies Ltd - History
Living Cell Technologies Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Living Cell Technologies Ltd - Business Description
Living Cell Technologies Ltd - Corporate Strategy
Living Cell Technologies Ltd - SWOT Analysis
SWOT Analysis - Overview
Living Cell Technologies Ltd - Strengths
Living Cell Technologies Ltd - Weaknesses
Living Cell Technologies Ltd - Opportunities
Living Cell Technologies Ltd - Threats
Living Cell Technologies Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Living Cell Technologies Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 16, 2021: LCT appoints interim CEO
Jan 25, 2021: LCT CEO Dr Ken Taylor signals intention to retire

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Living Cell Technologies Ltd, Key Facts
Living Cell Technologies Ltd, Key Employees
Living Cell Technologies Ltd, Key Employee Biographies
Living Cell Technologies Ltd, Major Products and Services
Living Cell Technologies Ltd, History
Living Cell Technologies Ltd, Other Locations
Living Cell Technologies Ltd, Subsidiaries
Living Cell Technologies Ltd, Joint Venture
Living Cell Technologies Ltd, Key Competitors
Living Cell Technologies Ltd, Ratios based on current share price
Living Cell Technologies Ltd, Annual Ratios
Living Cell Technologies Ltd, Annual Ratios (Cont...1)
Living Cell Technologies Ltd, Interim Ratios
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Living Cell Technologies Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Living Cell Technologies Ltd, Performance Chart (2017 - 2021)
Living Cell Technologies Ltd, Ratio Charts
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021